Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer

Stopped Study early termination was due to slow recruitment and difficulties at achieving the required enrolment for the study.

Conditions

• Lung Cancer, Non-Small Cell

Interventions

• BIOLOGICAL: Immunotherapeutic GSK1572932A
• DRUG: Cisplatin (CDDP)
• DRUG: Vinorelbine
• PROCEDURE: Radiotherapy

Sponsor

GlaxoSmithKline